Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
ARMP

ARMP - Armata Pharmaceuticals Inc Stock Price, Fair Value and News

$6.53-0.06 (-0.91%)
Market Closed

2/100

ARMP

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

2/100

ARMP

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$4.8

Target 3M

$5.4

Target 6M

$5.1

ARMP Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ARMP Price Action

Last 7 days

9.2%

Last 30 days

2.7%

Last 90 days

31.7%

Trailing 12 Months

213.9%

ARMP RSI Chart

ARMP Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ARMP Valuation

Market Cap

237.2M

Price/Earnings (Trailing)

-5.06

Price/Sales (Trailing)

46.94

EV/EBITDA

-32.77

Price/Free Cashflow

-8.65

ARMP Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$4.8

Target 3M

$5.4

Target 6M

$5.1

ARMP Fundamentals

ARMP Revenue

Revenue (TTM)

5.1M

Rev. Growth (Yr)

-61.02%

Rev. Growth (Qtr)

-46.57%

ARMP Earnings

Earnings (TTM)

-46.9M

Earnings Growth (Yr)

-386.68%

Earnings Growth (Qtr)

-63.7%

ARMP Profitability

EBT Margin

-333.22%

Return on Equity

49.07%

Return on Assets

-52.39%

Free Cashflow Yield

-11.56%

ARMP Investor Care

Shares Dilution (1Y)

0.41%

Diluted EPS (TTM)

-1.43

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20254.7M6.9M5.1M0
20244.7M3.7M5.5M5.2M
20235.1M4.2M4.1M4.5M
20224.6M5.4M5.4M5.5M
20211.7M2.6M3.6M4.5M
20200351.0K587.0K823.0K
2017183.0K108.0K117.0K115.0K
2016479.0K480.0K366.0K260.0K
2015407.0K408.0K448.0K475.0K
2014163.0K245.0K327.0K409.0K
201300081.0K
Get all data in R, Python etc through our Historical Stock Data APIs

About Armata Pharmaceuticals Inc

ARMP
Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has research collaboration agreement with Merck Sharp & Dohme Corp. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Marina del Rey, California.
 CEO
 WEBSITEarmatapharma.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES72

Armata Pharmaceuticals Inc Frequently Asked Questions

ARMP is the stock ticker symbol of Armata Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Armata Pharmaceuticals Inc is 237.23 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check ARMP's fair value in chart for subscribers.

The fair value guage provides a quick view whether ARMP is over valued or under valued. Whether Armata Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Armata Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ARMP.

As of Wed Jan 28 2026, ARMP's PE ratio (Price to Earnings) is -5.06 and Price to Sales (PS) ratio is 46.94. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ARMP PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Armata Pharmaceuticals Inc has provided -0.341 (multiply by 100 for percentage) rate of return.